If approved, Opill would be the first daily oral contraceptive pill available without a prescription.
News and Features
Placement at 2 to 4 weeks postpartum noninferior to 6 to 8 weeks postpartum for complete expulsion.
Increased relative risks noted for current or recent use of oral, injected, implanted, IUD progestogen-only contraceptives.
Net monetary benefit from group B Streptococcus vaccination estimated to range from $1.1 to $17 billion
Prevalence of pregnancy and incidence of conception were lower for phentermine-topiramate vs topiramate and other antiobesity meds.
In subgroup analyses, lower risk was seen with cumulative dosage of 401mg or greater, or with therapy duration of 5 years or longer.
Mean annualized relapse rate not different before vs after controlled ovarian stimulation.
Study shows that polygenic score does not modify the 13 percent reduction in ovarian cancer risk seen with aspirin
More than half of U.S. abortions in 2020 were completed by medication instead of surgery
Aspirin discontinuation at 24 to 28 weeks gestation noninferior to continuation until 36 weeks of gestation
No signs of higher risk seen for developmental disorders
Findings seen for school performance at age 12 years and lower-secondary school achievement
Women with migraine, regular menstrual cycle have higher CGRP in plasma, tear fluid during menstruation than those without migraine
Daily supplement of 0.4 to 0.8 mg recommended for people planning to or who could become pregnant
Adverse outcomes included small for gestational age, medically indicated preterm birth, stillbirth, or hypertensive disorders of pregnancy
The BLA is supported by data from a phase 3 trial which included approximately 7400 pregnant individuals.
Device is safe and effective in real-world setting, providing high treatment success for vaginal and cesarean births
Lawsuit alleges that the FDA should not have used an accelerated review process for mifepristone
The conversion to regular approval was based on data from an additional 141 patients with dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen.
The study analyzed 29,278 women who were in labor at 28 weeks’ gestation or more and who were planning a vaginal delivery.